The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review" report has been added to ResearchAndMarkets.com's offering.

More information: Thomas A. Hope et al, SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET, Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.124.269002 ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

The procedure standard/practice guideline outlines several oncologic indications for FAP PET imaging, including gastro-intestinal adenocarcinoma, pancreatic ductal adenocarcinoma, esophageal, head ...